Last year, while browsing on Aim for a target company to reverse-merge his business into, Dubliner Gerry Brandon spotted something interesting. The potential target company was called Integumen. It was a disaster of a business, with the distinction of being the worst-performing Aim flotation in 2017. By mid-2018 it was as good as dead, with a market cap of £1.2 million. Integumen listed as a loose collection of skincare products and lab science. The idea was that some of the skin products were ready for the market, others were still at R&D stage, and that somehow the thing would hang…

Join The Currency

INTRODUCTORY OFFER: Full annual membership for just €200.

Don’t miss out on what is going on with our daily unique stories from our team of skilled journalists and insightful commentators.

Members of The Currency get full access to over 4,000 exclusive interviews, investigations, and analysis, plus over 460 podcasts.

Annual membership is just €200 for the first year, a saving of €100.

Or try The Currency for the first month for a special introductory rate of €5, a saving of €20.

Cancel at any time.

To become a member today click here.